Red cell enzymes and plasma protein polymorphisms in the population of Cabo Verde (West Africa)

E J Parra1, J C Teixeira Ribeiro2, A Riveiro1

  • 1Departamento de Antropoloxía, Facultade de Bioloxía, Universidade de Santiago, 15706 Santiago de Compostela, Galicia, Spain.

Insights

Genetic analysis of red cell enzymes and plasma proteins in Cabo Verde reveals intermediate frequencies between African and European populations. This suggests significant European contribution to the West African gene pool.

Area of Science:

  • Population Genetics
  • Human Genetics
  • Biochemistry

Background:

  • The population of Cabo Verde, founded in the 15th century, has a unique demographic history.
  • It was established by West African slaves and European settlers, primarily Portuguese.

Purpose of the Study:

  • To analyze the genetic polymorphism of red cell enzymes and plasma proteins in the Cabo Verdean population.
  • To determine the genetic contribution of African and European ancestries.

Main Methods:

  • Analysis of genetic polymorphism for six red cell enzymes (ADA, AK1, ALAD, ESD, GLO1, PGD).
  • Analysis of genetic polymorphism for ten plasma proteins (AHSG, BF, F13A, F13B, GC, HP, ORM, PLG, TBG, TF).
  • Study conducted on 268 unrelated individuals from Cabo Verde.

Main Results:

  • Allele frequencies for most markers were intermediate between African and European populations.
  • Specific alleles, rare in Africans but common in Europeans, were identified.
  • This indicates a mixed genetic heritage in the Cabo Verdean population.

Conclusions:

  • The genetic profile of Cabo Verdeans reflects a substantial European admixture.
  • The study highlights the complex genetic makeup resulting from historical population movements.

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
65
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450...
53
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
56
Drug toxicity: Idiosyncratic Reactions01:16

Drug toxicity: Idiosyncratic Reactions

Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...
74
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
68
Blood Transfusion and Agglutination02:45

Blood Transfusion and Agglutination

Blood transfusion is a therapeutic measure to restore the blood volume after extensive blood loss due to an accident or a medical procedure. Blood transfusion involves drawing a certain amount of blood from a suitable donor and infusing it into the recipient.
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...
15.1K